Breaking News Instant updates and real-time market news.

MGTA

Magenta Therapeutics

$10.36 /

-0.2 (-1.89%)

07:48
06/11/20
06/11
07:48
06/11/20
07:48

Magenta Therapeutics to discontinue enrollment in Phase 2 study in IMDs

Magenta Therapeutics provided a portfolio update across its most advanced programs. Magenta is developing MGTA-145 for a broad range of diseases, including autoimmune diseases, blood cancers and genetic diseases. The recently completed Phase 1 study in healthy donors showed that MGTA-145, in combination with plerixafor, enables safe, same-day dosing, mobilization and collection of sufficient functional hematopoietic stem cells for transplant. Based on the results of the Phase 1 study and a productive end of Phase 1 meeting with the FDA, Magenta intends to initiate multiple Phase 2 trials of MGTA-145 to include both allogeneic and autologous transplant settings, with up to 150,000 patients eligible annually in the U.S. and Europe. There is potential for Magenta to generate initial Phase 2 data on MGTA-145 in 2020. In May, the FDA's Office of Orphan Products and Development granted orphan drug designation to MGTA-145 for the mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent transplant. The company's most advanced conditioning program is on track to complete IND-enabling toxicology studies and progress GMP manufacturing in 2020, and Magenta expects to deliver initial clinical data in 2021. In May, Magenta announced a research and clinical collaboration with AVROBIO to evaluate the potential utility of MGTA-117 for conditioning patients with lysosomal storage disorders before they receive one of AVROBIO's investigational lentiviral gene therapies. Magenta presented preclinical data on its CD45-ADC program at the European League Against Rheumatism annual meeting last week demonstrating that a single dose of CD45-ADC removed disease-causing reactive T cells, enabling successful immune reset to halt disease progression and was well tolerated in three models of autoimmune disease: multiple sclerosis, systemic sclerosis and inflammatory arthritis. Magenta has identified a lead antibody for this program, and IND-enabling work on CD45-ADC is progressing in 2020. Magenta has made the strategic decision to discontinue enrollment in the Phase 2 study in IMDs. This decision was the result of several factors: enrollment challenges common to rare disease populations, particularly during the COVID-19 pandemic; a growing understanding in the field of the current challenges of allogeneic stem cell transplant in patients with non-malignant diseases, such as IMDs; and feedback from the FDA on endpoints and clinical trial design for registration. Enrollment in the Phase 2 investigator-initiated trial in patients with blood cancers is expected to be completed soon. The Company will use these data to inform a decision regarding future program development in blood cancers.

MGTA Magenta Therapeutics
$10.36 /

-0.2 (-1.89%)

06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs

TODAY'S FREE FLY STORIES

Options
SmileDirectClub call volume above normal and directionally bullish » 12:45
07/13/20
07/13
12:45
07/13/20
12:45
SDC

SmileDirectClub

$9.03 /

+0.79 (+9.59%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SDC SmileDirectClub
$9.03 /

+0.79 (+9.59%)

SDC SmileDirectClub
$9.03 /

+0.79 (+9.59%)

07/12/20 Stifel
Stifel likes near-term setup for SmileDirectClub, ups price target to $11
06/25/20
Fly Intel: Top five analyst initiations
06/25/20 Stephens
Stephens starts SmileDirectClub at Overweight with $11 price target
06/24/20 Stephens
SmileDirectClub initiated with an Overweight at Stephens
SDC SmileDirectClub
$9.03 /

+0.79 (+9.59%)

  • 12
    Sep
SDC SmileDirectClub
$9.03 /

+0.79 (+9.59%)

SDC SmileDirectClub
$9.03 /

+0.79 (+9.59%)

SDC SmileDirectClub
$9.03 /

+0.79 (+9.59%)

General news
Dallas Federal Reserve Bank President Robert Kaplan Speech to be released at 13:00  12:45
07/13/20
07/13
12:45
07/13/20
12:45
 
Conference/Events
National Press Club hosts a virtual event » 12:45
07/13/20
07/13
12:45
07/13/20
12:45

Federal Reserve Bank of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
JPMorgan backs Neutral on Philips ahead of Q2 results » 12:42
07/13/20
07/13
12:42
07/13/20
12:42
PHG

Philips

$48.94 /

+1.74 (+3.69%)

JPMorgan analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PHG Philips
$48.94 /

+1.74 (+3.69%)

PHG Philips
$48.94 /

+1.74 (+3.69%)

07/09/20 Morgan Stanley
Philips price target raised to EUR 45 from EUR 44.11 at Morgan Stanley
06/22/20 Barclays
Philips price target raised to EUR 52 from EUR 50 at Barclays
04/22/20 Morgan Stanley
Philips price target lowered to EUR 45 from EUR 50 at Morgan Stanley
04/21/20 JPMorgan
Philips price target raised to EUR 36.80 from EUR 33.90 at JPMorgan
PHG Philips
$48.94 /

+1.74 (+3.69%)

Recommendations
JPMorgan backs Neutral on Intrum after Q2 pre-announcement » 12:41
07/13/20
07/13
12:41
07/13/20
12:41
ITJTY

Intrum

$0.00 /

+ (+0.00%)

JPMorgan analyst Gurjit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ITJTY Intrum
$0.00 /

+ (+0.00%)

12:08 Today UBS
Intrum Q2 pre-announcement better-than-expected, says UBS
05/13/20 UBS
Intrum price target lowered to SEK 135 from SEK 165 at UBS
03/31/20 JPMorgan
Intrum price target lowered to SEK 155 from SEK 295 at JPMorgan
On The Fly
Fly Insider: 89Bio, Aprea among week's notable insider trades » 12:40
07/13/20
07/13
12:40
07/13/20
12:40
ETNB

89bio

$33.16 /

+0.78 (+2.41%)

, VCNX

Vaccinex

$4.81 /

+0.86 (+21.77%)

, WTI

W&T Offshore

$2.36 /

+0.055 (+2.39%)

, COO

Cooper Companies

$288.19 /

-1.02 (-0.35%)

, SYNH

Syneos Health

$57.99 /

+1.58 (+2.80%)

, ADPT

Adaptive Biotechnologies

$47.00 /

+1.04 (+2.26%)

, ALNY

Alnylam

$161.08 /

-1.25 (-0.77%)

, BILL

Bill.com

$90.35 /

+0.66 (+0.74%)

, CIEN

Ciena

$54.81 /

-0.17 (-0.31%)

, APRE

Aprea Therapeutics

$29.35 /

-0.12 (-0.41%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
ETNB 89bio
$33.16 /

+0.78 (+2.41%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

07/07/20 Chardan
89bio initiated with a Buy at Chardan
12/09/19 Oppenheimer
89bio initiated with an Outperform at Oppenheimer
12/09/19 SVB Leerink
89bio initiated with an Outperform at SVB Leerink
12/09/19 RBC Capital
89bio initiated with an Outperform at RBC Capital
VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

04/17/20 Roth Capital
W&T Offshore upgraded to Buy from Neutral at Roth Capital
03/13/20 Roth Capital
W&T Offshore downgraded to Neutral from Buy at Roth Capital
03/09/20 Stifel
W&T Offshore downgraded to Hold from Buy at Stifel
COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

07/06/20 Baird
Cooper Companies downgraded to Neutral, Baird see confluence of issues
07/06/20 Baird
Cooper Companies downgraded to Neutral from Outperform at Baird
06/05/20 UBS
UBS backs Buy on Alcon after Cooper results
05/26/20 Stephens
Cooper Companies price target raised to $325 from $300 at Stephens
SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

04/03/20 Mizuho
Syneos Health price target lowered to $42 from $56 at Mizuho
04/02/20 Credit Suisse
Syneos Health price target lowered to $62 from $72 at Credit Suisse
03/30/20 Goldman Sachs
Syneos Health downgraded to Neutral from Buy at Goldman Sachs
03/17/20 SunTrust
SunTrust cuts price targets across CROs, downgrades MedPace
ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

06/18/20 Guggenheim
Adaptive to benefit from increased MRD testing by oncologists, says Guggenheim
06/03/20
Fly Intel: Top five analyst initiations
06/03/20 Goldman Sachs
Adaptive Biotechnologies initiated with a Buy at Goldman Sachs
05/19/20 Guggenheim
Adaptive Biotechnologies price target raised to $50 from $44 at Guggenheim
ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BILL Bill.com
$90.35 /

+0.66 (+0.74%)

06/29/20 Goldman Sachs
Bill.com price target raised to $90 from $60 at Goldman Sachs
05/28/20
Fly Intel: Top five analyst upgrades
05/28/20 Piper Sandler
Bill.com upgraded to Overweight from Neutral at Piper Sandler
05/18/20 KeyBanc
Bill.com price target raised to $85 from $76 at KeyBanc
CIEN Ciena
$54.81 /

-0.17 (-0.31%)

06/05/20 JPMorgan
JPMorgan ups Ciena target to $63 from $53, adds to Analyst Focus List
06/05/20 Stifel
Ciena price target raised to $61 from $54 at Stifel
06/05/20 Cowen
Ciena price target raised to $73 from $69 at Cowen
06/05/20 Barclays
Ciena price target raised to $67 from $48 at Barclays
APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

06/22/20
Fly Intel: Top five analyst initiations
06/22/20 H.C. Wainwright
Aprea Therapeutics initiated with a Neutral at H.C. Wainwright
04/21/20
Fly Intel: Top five analyst initiations
04/20/20
Baird starts Aprea Therapeutics with Outperform on APR-246 potential
ETNB 89bio
$33.16 /

+0.78 (+2.41%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

ALNY Alnylam
$161.08 /

-1.25 (-0.77%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

APRE Aprea Therapeutics
$29.35 /

-0.12 (-0.41%)

  • 08
    Jul
  • 11
    Jun
  • 24
    Jan
  • 12
    Dec
  • 11
    Nov
  • 03
    Oct
SYNH Syneos Health
$57.99 /

+1.58 (+2.80%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

ETNB 89bio
$33.16 /

+0.78 (+2.41%)

VCNX Vaccinex
$4.81 /

+0.86 (+21.77%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

COO Cooper Companies
$288.19 /

-1.02 (-0.35%)

ADPT Adaptive Biotechnologies
$47.00 /

+1.04 (+2.26%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

WTI W&T Offshore
$2.36 /

+0.055 (+2.39%)

BILL Bill.com
$90.35 /

+0.66 (+0.74%)

CIEN Ciena
$54.81 /

-0.17 (-0.31%)

Recommendations
JPMorgan backs Underweight on Getinge ahead of Q2 results » 12:39
07/13/20
07/13
12:39
07/13/20
12:39
GNGBY

Getinge

$0.00 /

+ (+0.00%)

JPMorgan analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GNGBY Getinge
$0.00 /

+ (+0.00%)

GNGBY Getinge
$0.00 /

+ (+0.00%)

06/17/20 Berenberg
Getinge price target raised to SEK 220 from SEK 210 at Berenberg
06/12/20 JPMorgan
Getinge price target raised to SEK 158 from SEK 153 at JPMorgan
04/23/20 JPMorgan
Getinge price target raised to SEK 153 from SEK 150 at JPMorgan
04/17/20 JPMorgan
Getinge price target raised to SEK 150 from SEK 120 at JPMorgan
Recommendations
JPMorgan cautious on 'unfavorable' earnings momentum for Essity » 12:34
07/13/20
07/13
12:34
07/13/20
12:34
ESSYY

Essity

$0.00 /

+ (+0.00%)

JPMorgan analyst Celine…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ESSYY Essity
$0.00 /

+ (+0.00%)

07/01/20 UBS
Essity price target lowered to SEK 316 from SEK 320
03/17/20 JPMorgan
Essity upgraded to Overweight from Neutral at JPMorgan
03/17/20 JPMorgan
Essity upgraded to Overweight from Neutral at JPMorgan
01/08/20 Goldman Sachs
Essity downgraded to Sell from Neutral at Goldman Sachs
Periodicals
Applied Therapeutics amendment 'bolsters' short seller accusations, STAT says » 12:33
07/13/20
07/13
12:33
07/13/20
12:33
APLT

Applied Therapeutics

$30.07 /

-0.51 (-1.67%)

Applied Therapeutics told…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APLT Applied Therapeutics
$30.07 /

-0.51 (-1.67%)

APLT Applied Therapeutics
$30.07 /

-0.51 (-1.67%)

04/22/20
Fly Intel: Top five analyst initiations
04/22/20 Goldman Sachs
Applied Therapeutics initiated with a Buy at Goldman Sachs
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
02/27/20 Barclays
Applied Therapeutics initiated with an Overweight at Barclays
APLT Applied Therapeutics
$30.07 /

-0.51 (-1.67%)

  • 24
    Jan
APLT Applied Therapeutics
$30.07 /

-0.51 (-1.67%)

APLT Applied Therapeutics
$30.07 /

-0.51 (-1.67%)

Recommendations
Ericsson 'very well positioned' into 5G cycle, says JPMorgan » 12:32
07/13/20
07/13
12:32
07/13/20
12:32
ERIC

Ericsson

$9.55 /

+0.125 (+1.33%)

JPMorgan analyst Sandeep…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ERIC Ericsson
$9.55 /

+0.125 (+1.33%)

ERIC Ericsson
$9.55 /

+0.125 (+1.33%)

04/17/20 Credit Suisse
Ericsson price target raised to SEK 98 from SEK 97 at Credit Suisse
03/30/20 BofA
US 1 List changes at BofA
03/30/20 Cowen
Ericsson upgraded to Outperform from Market Perform at Cowen
03/27/20 Raymond James
Raymond James upgrades Ericsson with networking an essential service
ERIC Ericsson
$9.55 /

+0.125 (+1.33%)

ERIC Ericsson
$9.55 /

+0.125 (+1.33%)

ERIC Ericsson
$9.55 /

+0.125 (+1.33%)

ERIC Ericsson
$9.55 /

+0.125 (+1.33%)

Conference/Events
Wedbush specialty retail analyst to hold an analyst/industry conference call » 12:31
07/13/20
07/13
12:31
07/13/20
12:31
W

Wayfair

$223.81 /

+0.27 (+0.12%)

, BBBY

Bed Bath & Beyond

$7.84 /

-0.35 (-4.27%)

, HOME

At Home Group

$5.86 /

-0.09 (-1.51%)

, RH

RH

$270.20 /

+8.91 (+3.41%)

, WSM

Williams-Sonoma

$85.37 /

+0.2 (+0.23%)

Specialty Retail Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
W Wayfair
$223.81 /

+0.27 (+0.12%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.86 /

-0.09 (-1.51%)

RH RH
$270.20 /

+8.91 (+3.41%)

WSM Williams-Sonoma
$85.37 /

+0.2 (+0.23%)

W Wayfair
$223.81 /

+0.27 (+0.12%)

07/07/20 Baird
Wayfair price target raised to $225 from $190 at Baird
07/01/20 Deutsche Bank
Farfetch price target raised to $23 from $17 at Deutsche Bank
06/26/20 SunTrust
Wayfair price target raised to $208 from $163 at SunTrust
06/26/20 Wells Fargo
Wayfair price target raised to $215 from $170 at Wells Fargo
BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

07/10/20 Loop Capital
Bed Bath & Beyond price target raised to $9 from $5 at Loop Capital
07/07/20 Raymond James
Bed Bath & Beyond price target raised to $13 from $9 at Raymond James
05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
HOME At Home Group
$5.86 /

-0.09 (-1.51%)

06/23/20 Loop Capital
Loop sees At Home, Dollar Tree as potential targets for activists
06/19/20 Loop Capital
At Home Group price target raised to $7 from $3 at Loop Capital
03/25/20 Guggenheim
Guggenheim cuts At Home Group to Neutral on 'unprecedented demand uncertainty'
03/25/20 Guggenheim
At Home Group downgraded to Neutral from Buy at Guggenheim
RH RH
$270.20 /

+8.91 (+3.41%)

06/16/20 Goldman Sachs
RH price target raised to $232 from $120 at Goldman Sachs
06/15/20 Loop Capital
RH upgraded to Buy from Hold at Loop Capital
06/15/20 Loop Capital
RH upgraded to Buy from Hold at Loop Capital
06/08/20 Loop Capital
RH price target raised to $250 from $110 at Loop Capital
WSM Williams-Sonoma
$85.37 /

+0.2 (+0.23%)

06/18/20
Fly Intel: Top five analyst initiations
06/18/20 Wells Fargo
Williams-Sonoma initiated with an Equal Weight at Wells Fargo
06/05/20 Argus
Williams-Sonoma price target raised to $95 from $80 at Argus
06/01/20 Loop Capital
Williams-Sonoma price target raised to $80 from $40 at Loop Capital
W Wayfair
$223.81 /

+0.27 (+0.12%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.86 /

-0.09 (-1.51%)

RH RH
$270.20 /

+8.91 (+3.41%)

WSM Williams-Sonoma
$85.37 /

+0.2 (+0.23%)

W Wayfair
$223.81 /

+0.27 (+0.12%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

RH RH
$270.20 /

+8.91 (+3.41%)

WSM Williams-Sonoma
$85.37 /

+0.2 (+0.23%)

W Wayfair
$223.81 /

+0.27 (+0.12%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.86 /

-0.09 (-1.51%)

RH RH
$270.20 /

+8.91 (+3.41%)

WSM Williams-Sonoma
$85.37 /

+0.2 (+0.23%)

W Wayfair
$223.81 /

+0.27 (+0.12%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.86 /

-0.09 (-1.51%)

RH RH
$270.20 /

+8.91 (+3.41%)

WSM Williams-Sonoma
$85.37 /

+0.2 (+0.23%)

Recommendations
Carlsberg H1 profit surprise should de-risk rest of 2020, says JPMorgan » 12:30
07/13/20
07/13
12:30
07/13/20
12:30
CABGY

Carlsberg

$0.00 /

+ (+0.00%)

JPMorgan analyst Fintan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CABGY Carlsberg
$0.00 /

+ (+0.00%)

CABGY Carlsberg
$0.00 /

+ (+0.00%)

11:56 Today Citi
Carlsberg 'surprised the market' with H1 pre-announcement, says Citi
11:48 Today Morgan Stanley
Carlsberg price target raised to DKK 1,000 from DKK 955 at Morgan Stanley
07/09/20 UBS
Carlsberg price target raised to DKK 720 from DKK 660 at UBS
07/02/20 Barclays
Carlsberg price target raised to DKK 988 from DKK 923 at Barclays
Recommendations
JPMorgan sees Aeroports de Paris H1 revenue falling EUR1B y/y » 12:28
07/13/20
07/13
12:28
07/13/20
12:28
AEOXF

Aeroports de Paris

$0.00 /

+ (+0.00%)

JPMorgan analyst Elodie…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AEOXF Aeroports de Paris
$0.00 /

+ (+0.00%)

06/25/20 Barclays
Aeroports de Paris price target lowered to EUR 72 from EUR 79 at Barclays
06/24/20 BofA
Aeroports de Paris downgraded to Underperform from Neutral at BofA
06/18/20 JPMorgan
Aeroports de Paris downgraded to Underweight from Neutral at JPMorgan
05/27/20 Goldman Sachs
Aeroports de Paris price target lowered to EUR 89 from EUR 99 at Goldman Sachs
Periodicals
Macau gets boost as neighboring province lifts quarantine rules, Bloomberg says » 12:26
07/13/20
07/13
12:26
07/13/20
12:26
LVS

Las Vegas Sands

$49.09 /

+3.37 (+7.37%)

, WYNN

Wynn Resorts

$81.98 /

+7.83 (+10.56%)

, MGM

MGM Resorts

$16.90 /

+0.71 (+4.39%)

, MLCO

Melco Resorts & Entertainment

$17.87 /

+2.27 (+14.55%)

Macau's neighboring…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LVS Las Vegas Sands
$49.09 /

+3.37 (+7.37%)

WYNN Wynn Resorts
$81.98 /

+7.83 (+10.56%)

MGM MGM Resorts
$16.90 /

+0.71 (+4.39%)

MLCO Melco Resorts & Entertainment
$17.87 /

+2.27 (+14.55%)

LVS Las Vegas Sands
$49.09 /

+3.37 (+7.37%)

05/21/20
Fly Intel: Top five analyst upgrades
05/21/20 Credit Suisse
Credit Suisse upgrades Las Vegas Sands to Outperform with $58 target
05/21/20 Credit Suisse
Las Vegas Sands assumed with an Outperform from Neutral at Credit Suisse
05/06/20 Roth Capital
Las Vegas Sands price target lowered to $52 from $69 at Roth Capital
WYNN Wynn Resorts
$81.98 /

+7.83 (+10.56%)

06/11/20 JPMorgan
Wynn Resorts' Macau SAR results better than feared, says JPMorgan
05/27/20 Roth Capital
Wynn video 'clearly shows' Remark AI technology in use, says Roth Capital
05/21/20 Credit Suisse
Wynn Resorts assumed with a Neutral at Credit Suisse
05/07/20 Roth Capital
Wynn Resorts price target lowered to $99 from $104 at Roth Capital
MGM MGM Resorts
$16.90 /

+0.71 (+4.39%)

07/08/20 Jefferies
GVC has 'credible' U.S. sports betting aspirations, says Jefferies
06/12/20 SunTrust
SunTrust raises price target on select Gaming names amid positive room-rate data
06/10/20 Wolfe Research
MGM Resorts downgraded to Peer Perform from Outperform at Wolfe Research
05/21/20
Fly Intel: Top five analyst downgrades
MLCO Melco Resorts & Entertainment
$17.87 /

+2.27 (+14.55%)

05/15/20 Roth Capital
Melco Resorts & Entertainment the 'best Macau name,' says Roth Capital
04/20/20 Nomura Instinet
Melco price target lowered to $20 from $27 at Nomura Instinet
02/04/20 Bernstein
Bernstein sees Macau having 'solid' recovery in second half of 2020
01/28/20 JPMorgan
JPMorgan sees value in Gaming 'carnage,' Melco is top pick
LVS Las Vegas Sands
$49.09 /

+3.37 (+7.37%)

WYNN Wynn Resorts
$81.98 /

+7.83 (+10.56%)

MGM MGM Resorts
$16.90 /

+0.71 (+4.39%)

MLCO Melco Resorts & Entertainment
$17.87 /

+2.27 (+14.55%)

LVS Las Vegas Sands
$49.09 /

+3.37 (+7.37%)

WYNN Wynn Resorts
$81.98 /

+7.83 (+10.56%)

MGM MGM Resorts
$16.90 /

+0.71 (+4.39%)

MLCO Melco Resorts & Entertainment
$17.87 /

+2.27 (+14.55%)

LVS Las Vegas Sands
$49.09 /

+3.37 (+7.37%)

WYNN Wynn Resorts
$81.98 /

+7.83 (+10.56%)

MGM MGM Resorts
$16.90 /

+0.71 (+4.39%)

MLCO Melco Resorts & Entertainment
$17.87 /

+2.27 (+14.55%)

LVS Las Vegas Sands
$49.09 /

+3.37 (+7.37%)

WYNN Wynn Resorts
$81.98 /

+7.83 (+10.56%)

MGM MGM Resorts
$16.90 /

+0.71 (+4.39%)

MLCO Melco Resorts & Entertainment
$17.87 /

+2.27 (+14.55%)

Options
Chewy call volume above normal and directionally bullish » 12:25
07/13/20
07/13
12:25
07/13/20
12:25
CHWY

Chewy

$51.73 /

+3.16 (+6.51%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CHWY Chewy
$51.73 /

+3.16 (+6.51%)

CHWY Chewy
$51.73 /

+3.16 (+6.51%)

06/10/20 RBC Capital
Chewy price target raised to $62 from $40 at RBC Capital
06/10/20 JPMorgan
Chewy price target raised to $65 from $43 at JPMorgan
06/10/20 Credit Suisse
Chewy price target raised to $53 from $46 at Credit Suisse
06/10/20 Barclays
Chewy shares already reflect bullish outlook, says Barclays
CHWY Chewy
$51.73 /

+3.16 (+6.51%)

CHWY Chewy
$51.73 /

+3.16 (+6.51%)

CHWY Chewy
$51.73 /

+3.16 (+6.51%)

CHWY Chewy
$51.73 /

+3.16 (+6.51%)

Conference/Events
Wedbush retail/hardlines analyst to hold an analyst/industry conference call » 12:25
07/13/20
07/13
12:25
07/13/20
12:25
W

Wayfair

$223.00 /

-0.54 (-0.24%)

, BBBY

Bed Bath & Beyond

$7.84 /

-0.35 (-4.27%)

, HOME

At Home Group

$5.90 /

-0.055 (-0.92%)

, RH

RH

$273.02 /

+11.73 (+4.49%)

, WSM

Williams-Sonoma

$85.66 /

+0.49 (+0.58%)

Retail/Hardlines Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
W Wayfair
$223.00 /

-0.54 (-0.24%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.90 /

-0.055 (-0.92%)

RH RH
$273.02 /

+11.73 (+4.49%)

WSM Williams-Sonoma
$85.66 /

+0.49 (+0.58%)

W Wayfair
$223.00 /

-0.54 (-0.24%)

07/07/20 Baird
Wayfair price target raised to $225 from $190 at Baird
07/01/20 Deutsche Bank
Farfetch price target raised to $23 from $17 at Deutsche Bank
06/26/20 SunTrust
Wayfair price target raised to $208 from $163 at SunTrust
06/26/20 Wells Fargo
Wayfair price target raised to $215 from $170 at Wells Fargo
BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

07/10/20 Loop Capital
Bed Bath & Beyond price target raised to $9 from $5 at Loop Capital
07/07/20 Raymond James
Bed Bath & Beyond price target raised to $13 from $9 at Raymond James
05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
HOME At Home Group
$5.90 /

-0.055 (-0.92%)

06/23/20 Loop Capital
Loop sees At Home, Dollar Tree as potential targets for activists
06/19/20 Loop Capital
At Home Group price target raised to $7 from $3 at Loop Capital
03/25/20 Guggenheim
Guggenheim cuts At Home Group to Neutral on 'unprecedented demand uncertainty'
03/25/20 Guggenheim
At Home Group downgraded to Neutral from Buy at Guggenheim
RH RH
$273.02 /

+11.73 (+4.49%)

06/16/20 Goldman Sachs
RH price target raised to $232 from $120 at Goldman Sachs
06/15/20 Loop Capital
RH upgraded to Buy from Hold at Loop Capital
06/15/20 Loop Capital
RH upgraded to Buy from Hold at Loop Capital
06/08/20 Loop Capital
RH price target raised to $250 from $110 at Loop Capital
WSM Williams-Sonoma
$85.66 /

+0.49 (+0.58%)

06/18/20
Fly Intel: Top five analyst initiations
06/18/20 Wells Fargo
Williams-Sonoma initiated with an Equal Weight at Wells Fargo
06/05/20 Argus
Williams-Sonoma price target raised to $95 from $80 at Argus
06/01/20 Loop Capital
Williams-Sonoma price target raised to $80 from $40 at Loop Capital
W Wayfair
$223.00 /

-0.54 (-0.24%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.90 /

-0.055 (-0.92%)

RH RH
$273.02 /

+11.73 (+4.49%)

WSM Williams-Sonoma
$85.66 /

+0.49 (+0.58%)

W Wayfair
$223.00 /

-0.54 (-0.24%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

RH RH
$273.02 /

+11.73 (+4.49%)

WSM Williams-Sonoma
$85.66 /

+0.49 (+0.58%)

W Wayfair
$223.00 /

-0.54 (-0.24%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.90 /

-0.055 (-0.92%)

RH RH
$273.02 /

+11.73 (+4.49%)

WSM Williams-Sonoma
$85.66 /

+0.49 (+0.58%)

W Wayfair
$223.00 /

-0.54 (-0.24%)

BBBY Bed Bath & Beyond
$7.84 /

-0.35 (-4.27%)

HOME At Home Group
$5.90 /

-0.055 (-0.92%)

RH RH
$273.02 /

+11.73 (+4.49%)

WSM Williams-Sonoma
$85.66 /

+0.49 (+0.58%)

Conference/Events
UBS consumer services/products analysts hold an analyst/industry conference call » 12:25
07/13/20
07/13
12:25
07/13/20
12:25

Consumer Services &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Wolfe Research multi-industry analyst to hold analyst/industry webcast » 12:25
07/13/20
07/13
12:25
07/13/20
12:25

Multi-Industry Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Smartsheet participates in a conference call with Stephens » 12:25
07/13/20
07/13
12:25
07/13/20
12:25
SMAR

Smartsheet

$51.91 /

+0.44 (+0.85%)

Conference call with CFO…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SMAR Smartsheet
$51.91 /

+0.44 (+0.85%)

SMAR Smartsheet
$51.91 /

+0.44 (+0.85%)

07/08/20 DA Davidson
Smartsheet price target raised to $50 from $45 at DA Davidson
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Wells Fargo
Smartsheet initiated with an Equal Weight at Wells Fargo
06/04/20 DA Davidson
Smartsheet price target raised to $45 from $37 at DA Davidson
SMAR Smartsheet
$51.91 /

+0.44 (+0.85%)

SMAR Smartsheet
$51.91 /

+0.44 (+0.85%)

SMAR Smartsheet
$51.91 /

+0.44 (+0.85%)

Conference/Events
Nutanix participates in a conference call with JMP Securities » 12:25
07/13/20
07/13
12:25
07/13/20
12:25
NTNX

Nutanix

$22.95 /

-0.37 (-1.59%)

Cybersecurity & IT…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NTNX Nutanix
$22.95 /

-0.37 (-1.59%)

NTNX Nutanix
$22.95 /

-0.37 (-1.59%)

05/28/20 RBC Capital
Nutanix price target raised to $27 from $23 at RBC Capital
05/28/20 Wells Fargo
Nutanix price target raised to $27 from $22 at Wells Fargo
05/28/20 JMP Securities
Nutanix price target lowered to $45 from $52 at JMP Securities
05/21/20 JPMorgan
Nutanix price target lowered to $24 from $27 at JPMorgan
NTNX Nutanix
$22.95 /

-0.37 (-1.59%)

NTNX Nutanix
$22.95 /

-0.37 (-1.59%)

NTNX Nutanix
$22.95 /

-0.37 (-1.59%)

NTNX Nutanix
$22.95 /

-0.37 (-1.59%)

Conference/Events
Susquehanna social media analysts to hold an analyst/industry conference call » 12:25
07/13/20
07/13
12:25
07/13/20
12:25

Social Media Analysts,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call » 12:25
07/13/20
07/13
12:25
07/13/20
12:25

Biotechnology Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Jefferies software/Internet analyst to hold an analyst/industry conference call » 12:25
07/13/20
07/13
12:25
07/13/20
12:25
CTXS

Citrix

$153.47 /

+1.29 (+0.85%)

Software & Internet…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CTXS Citrix
$153.47 /

+1.29 (+0.85%)

CTXS Citrix
$153.47 /

+1.29 (+0.85%)

06/24/20 Goldman Sachs
Citrix price target raised to $172 from $154 at Goldman Sachs
04/24/20 Wells Fargo
Citrix price target raised to $165 from $150 at Wells Fargo
04/24/20 Deutsche Bank
Citrix price target raised to $200 from $175 at Deutsche Bank
04/24/20 Morgan Stanley
Citrix price target raised to $165 from $160 at Morgan Stanley
CTXS Citrix
$153.47 /

+1.29 (+0.85%)

CTXS Citrix
$153.47 /

+1.29 (+0.85%)

CTXS Citrix
$153.47 /

+1.29 (+0.85%)

Conference/Events
IGM Biosciences participates in a conference call with SunTrust » 12:24
07/13/20
07/13
12:24
07/13/20
12:24
IGMS

IGM Biosciences

$70.43 /

-0.21 (-0.30%)

Conference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IGMS IGM Biosciences
$70.43 /

-0.21 (-0.30%)

IGMS IGM Biosciences
$70.43 /

-0.21 (-0.30%)

07/01/20 H.C. Wainwright
IGM Biosciences initiated with a Buy at H.C. Wainwright
05/28/20 SunTrust
IGM Biosciences initiated with a Buy at SunTrust
05/28/20 SunTrust
IGM Biosciences initiated with a Buy at SunTrust
05/08/20 Stifel
IGM Biosciences price target raised to $67 from $60 at Stifel
IGMS IGM Biosciences
$70.43 /

-0.21 (-0.30%)

  • 18
    Sep
Recommendations
Millicom price target lowered to SEK 280 from SEK 320 at JPMorgan » 12:22
07/13/20
07/13
12:22
07/13/20
12:22
TIGO

Millicom

$25.52 /

-0.23 (-0.89%)

JPMorgan analyst Marcelo…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TIGO Millicom
$25.52 /

-0.23 (-0.89%)

04/06/20 New Street
Millicom downgraded to Neutral from Buy at New Street
03/12/20 Scotiabank
Millicom upgraded to Outperform from Sector Perform at Scotiabank
09/19/19 HSBC
Millicom upgraded to Buy from Hold at HSBC

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.